Cancer researchers publish study on avidity enhancement of CAR T cells
May 25, 2022 -- A team of cancer researchers led by Dr. Marcela Maus have published a preclinical study detailing the use of the Lumicks z-Movi Cell Avidity Analyzer to provide more nuanced development of cancer treatments. The study focused on using Lumicks’ technology to identify chimeric antigen receptor (CAR) T cells that are best suited to treat acute myeloid leukemia. Read More
Next-generation AAV capsids hold key to developing life-changing therapies
May 24, 2022 -- Voyager Therapeutics’ discovery platform is identifying novel capsids targeting desired cells and tissues with greater specificity, at lower doses, and with fewer off-target risks than conventional adeno-associated virus (AAV) serotypes in non-human primates, according to Todd Carter, PhD, senior vice president for research. The company presented data on the platform at the American Society of Gene & Cell Therapy 2022 annual meeting. Read More
Genenta Science reports preliminary results of Temferon-glioblastoma study
May 24, 2022 -- Biotech company Genenta Science is developing a proprietary hematopoietic stem cell gene therapy, Temferon, for the treatment of a variety of solid tumor cancers, according to co-founder Dr. Bernhard Gentner, PhD. ScienceBoard.net spoke to Gentner at the American Society of Gene & Cell Therapy 2022 annual meeting in Washington, DC, about Temferon. Read More
Atsena Therapeutics’ gene therapy takes aim at childhood blindness
May 23, 2022 -- In an interview with ScienceBoard.net, Patrick Ritschel, CEO of Ophthalmology-based gene therapy company Atsena Therapeutics, shared an overview of the company's development of novel treatments for inherited forms of blindness at the American Society of Gene & Cell Therapy 2022 annual meeting in Washington, DC. Read More
How to address challenges in producing AAV vectors
May 23, 2022 -- There are challenges in producing sufficient quantities of gene therapy products, particularly when it comes to adeno-associated virus (AAV) vectors, contends Ines do Carmo Gil-Goncalves, PhD, head of vector production for Cevec Pharmaceuticals GmbH. Gil-Goncalves discussed how Cevec’s Elevecta platform can help overcome these challenges at the American Society of Gene & Cell Therapy 2022 annual meeting. Read More
Omega Therapeutics looks to tap 'nature's operating system' to control gene expression
May 20, 2022 -- Precision genomic medicine company Omega Therapeutics is looking to harness “nature’s operating system” for controlling gene expression and cell differentiation, according to Thomas McCauley, PhD, chief scientific officer. McCauley spoke with ScienceBoard.net at the American Society of Gene & Cell Therapy annual meeting in Washington, DC. Read More
Delivery of gene therapies remains a key challenge
May 19, 2022 -- Gene therapy holds great promise for treating inherited disorders, cancers, and other diseases, but delivery of these therapies remains a key challenge, contends Kevin Foust, PhD, senior vice president for preclinical and translational medicine at Jaguar Gene Therapy. Foust spoke with ScienceBoard.net at the American Society of Gene & Cell Therapy annual meeting in Washington, DC. Read More
Next evolution of CAR T-cell therapy is solid tumors
May 18, 2022 -- While chimeric antigen receptor (CAR) T-cell therapy has become a game changer for some patients with blood cancer, the next area of evolution for the technology is solid tumors, said Sangamo CEO Sandy Macrae, PhD, at the American Society of Gene & Cell Therapy 2022 annual meeting in Washington, DC. Read More
Forge Biologics assembles scientific and manufacturing advisory board
May 18, 2022 -- Forge Biologics has created its new Scientific and Manufacturing Advisory Board filled with leaders in the field of gene therapy development and manufacturing. This independent panel represents Forge’s commitment to enhancing its gene therapy offerings through insights from experts in the field. Read More
Precision BioSciences presents preclinical data for gene editing therapies
May 17, 2022 -- Precision BioSciences is scheduled to display preclinical data for its Arcus-based gene editing studies at the American Society of Gene & Cell Therapy’s annual meeting in Washington, DC. The showcase will include two oral presentations and two posters highlighting gene editing study results. Read More
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Connect
